1.Research progress in the relation between interleukin and inflammatory bowel disease
Clinical Medicine of China 2017;33(6):572-576
Inflammatory bowel disease (IBD) is a group of chronic and non-specific intestinal inflammatory diseases of undetermined origin,which including ulcerative colitis (UC) and crohn's disease (CD).Interleukin(IL) is a kind of cytokines,and plays an vital role in growth,differentiation,immune response of immune cell.With a intensive study in the pathogenesis of IBD in the world,parts of IL were found and confirmed to be a important role in the progression of IBD,and will become a new hot spot in the research of the diagnosis and treatment of IBD.
2.Research progress in the relationship between vitamin and inflammatory bowel disease
Xiaofei PAN ; Shengmei SHI ; e Xiao' ZHANG ; Liting HAO ; Cunying MENG
Clinical Medicine of China 2017;33(10):957-960
Objective Inflammatory bowel disease(IBD)is an unexplained chronic and recurrent inflammatory disease of the intestine,including ulcerative colitis(UC)and Crohn′s disease(CD).At present, the etiology and pathogenesis of IBD are still not clear,and it is believed to be related to the environment, inheritance,infection,immunity and other factors.With the increase of people′s living standard and the economic and social development,the incidence of IBD in China is a rising trend year by year,the impact of diet on the incidence of IBD and the influence of nutritional support on the prognosis of IBD have attracted more and more attention.Vitamin is one of the seven nutrients and is an indispensable part of the health of the body.In recent years,some vitamins have been proved to be related with the occurrence and development of IBD.
3.Research progress on candidemia in patients with hematological malignancies
Cunying YAO ; Huafeng WANG ; Haitao MENG
Chinese Journal of Clinical Infectious Diseases 2019;12(4):296-301
With the administration of antibacterial drugs , chemotherapy agents and corticosteroids , the incidence of candidemia in patients with hematological malignancies has been increased greatly in recent years.Due to the absence of typical symptoms , the high proportions of non-albicans candida, high antifungal resistance rate and high mortality, the candidemia in these patients remains a challenge in clinic practice.In this article we review the recent progress on the epidemiology , diagnosis and treatments , the antifungal resistance and its molecular basis of candidemia in patients with hematological malignancies .